poster
Brilaroxazine (BXZ, RP5063) is an investigational drug in development by Reviva Pharmaceuticals for neuropsychiatric & inflammatory disorders. It is a serotonin-dopamine modulator displaying partial agonist activity at D2/3/4 & 5-HT1A/2A receptors & antagonist activity at 5 HT2B/7 receptors with binding affinity for 5-HT2B > D2.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Accept Privacy PolicyNotifications